Institutions | About Us | Help | Gaeilge
rian logo


Mark
Go Back
Can histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophies
Sundaramurthi, Husvinee; Rueckert, H.; Moran, Ailís; Reynolds, Alison; Kennedy, Breandán
British Pharmacological Society (BPS) Pharmacology 2017, London, England, 11-13 December 2017 Inherited retinal dystrophies (iRDs) affect 1 in 3000 people worldwide and effective treatment options are not widely available due to the genetic and clinical heterogeneity. Recently, histone deacetylase inhibitors (HDACi) have gained attention as a potential therapeutic option based on their neuroprotective effects within the retina. However, the benefits of HDACi remains highly controversial, and their downstream mechanism of action are yet to be thoroughly elucidated. Preliminary data from studies conducted has shown that treatment of zebrafish retinal mutant with HDACi, trichostatin A (TSA), could rescue visual capacity and retinal morphology. The current study is designed to address the suitability of HDACi as therapeutic options for iRDs using zebrafish models. Fighting Blindness
Keyword(s): Inherited retinal dystrophies (iRDs); Treatment options; Histone deacetylase inhibitors (HDACi); Neuroprotective effects; Retina; Visual capacity; Retinal morphology
Publication Date:
2019
Type: Other
Peer-Reviewed: Unknown
Language(s): English
Institution: University College Dublin
First Indexed: 2019-05-11 06:31:44 Last Updated: 2019-05-11 06:31:44